These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 2493429

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
    Johnson M, Miniter P, Andriole VT.
    J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
    Bayer AS, Blomquist IK, Kim KS.
    J Antimicrob Chemother; 1986 May; 17(5):641-9. PubMed ID: 2941403
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of ciprofloxacin, azlocillin, imipenem/cilastatin and tobramycin in a model of experimental septicemia due to Pseudomonas aeruginosa in neutropenic mice.
    Ulrich E, Trautmann M, Krause B, Bauernfeind A, Hahn H.
    Infection; 1989 May; 17(5):311-5. PubMed ID: 2599653
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.
    Norden CW, Shaffer MA.
    Antimicrob Agents Chemother; 1982 Jan; 21(1):62-5. PubMed ID: 6805423
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa.
    Wu YL, Scott EM, Po AL, Tariq VN.
    J Antimicrob Chemother; 1999 Sep; 44(3):389-92. PubMed ID: 10511408
    [Abstract] [Full Text] [Related]

  • 12. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT, Sheng MY, Zhang Y, Li Y.
    Zhonghua Yi Xue Za Zhi; 2011 May 31; 91(20):1427-31. PubMed ID: 21756818
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection.
    Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH.
    J Infect Dis; 1991 Sep 31; 164(3):499-506. PubMed ID: 1908000
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
    Bustamante CI, Wharton RC, Wade JC.
    Antimicrob Agents Chemother; 1990 Sep 31; 34(9):1814-5. PubMed ID: 2126693
    [Abstract] [Full Text] [Related]

  • 17. Absence of a postantibiotic effect in experimental Pseudomonas endocarditis treated with imipenem, with or without gentamicin.
    Hessen MT, Pitsakis PG, Levison ME.
    J Infect Dis; 1988 Sep 31; 158(3):542-8. PubMed ID: 3137272
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008.
    Reyes MP, Ali A, Mendes RE, Biedenbach DJ.
    Medicine (Baltimore); 2009 Sep 31; 88(5):294-301. PubMed ID: 19745688
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.